0000899243-20-032454.txt : 20201202 0000899243-20-032454.hdr.sgml : 20201202 20201202094612 ACCESSION NUMBER: 0000899243-20-032454 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201202 FILED AS OF DATE: 20201202 DATE AS OF CHANGE: 20201202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wegman Mark N CENTRAL INDEX KEY: 0001405235 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 201362584 MAIL ADDRESS: STREET 1: 43 OVERLOOK ROAD CITY: OSSINING STATE: NY ZIP: 10562 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 302-842-8450 MAIL ADDRESS: STREET 1: 2 RIGHTER PARKWAY, SUITE 200 CITY: WILMINGTON STATE: DE ZIP: 19803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-02 1 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001405235 Wegman Mark N C/O BIOSPECIFICS TECHNOLOGIES CORP. 2 RIGHTER PKWY, DE CORP CENTER II WILMINGTON DE 19803 1 0 1 0 Common Stock, $0.001 par value 2020-11-17 4 G 0 2400 0.00 D 66488 D Common Stock, $0.001 par value 2020-12-02 4 D 0 64762 D 1726 D Common Stock, $0.001 par value 2020-12-02 4 D 0 1726 D 0 D Common Stock, $0.001 par value 2020-12-02 4 D 0 935073 D 0 I See footnote On November 17, 2020, the reporting person transferred 2,400 shares of common stock to a charitable fund. Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 64,762 shares of common stock were exchanged for a cash payment of $5,731,437, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person. Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were cancelled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50). Upon the consummation of the Merger, 935,073 shares of common stock held by the MARITAL TRUST U/W/O EDWIN H WEGMAN DATED 08/10/06 (the "Trust") were exchanged for a cash payment of $82,753,960.50, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the Trust. These shares are held in trust on behalf of the reporting person. The reporting person is the co-trustee of the Trust. The reporting person disclaims beneficial ownership of the shares held by the Trust except to the extent of the reporting person's pecuniary interest therein. Mark N. Wegman, by Carl A. Valenstein, attorney-in-fact 2020-12-02